Board of directors
Peter Hentschel – Chairman
Peter has more than 30 years international experience within the Health Care and Life Science industry. Previous positions include CEO of Etac AB, Vice President of SCA Hygienes Incontinence Division and Senior Vice President of Mölnlycke Health Cares Wound Care and Surgical Divisions. Peter was actively involved in the sale of MHC to Apax in 2005. During the past 12 years Peter has had Chairman positions and board memberships in several listed /non listed companies. Presently, in addition to being Chairman of Reapplix, he is the Chairman of RLS Global AB and member of the board of Lumina Adhesives AB.
Ulf’s previous positions include President & CEO of NeoPharma AB; General Manager of Fresenius-Kabi AB; Executive Vice President Global Nutrition Division at Fresenius-Kabi and President & CEO of Pharmacia & Upjohn AS. In addition, he has, for the past 18 years held Chairman positions and board memberships with several listed/non-listed life science companies in Scandinavia including the Trade Association, IML. Ulf has founded and exited several companies in the life science sector. Currently he is a Board member of Acarix AB/Acarix A/S, Curasight ApS, Lobsor Holding AB (Chairman), Intrance Holding AB (Chairman) and Intrance Medical Systems Inc. (Chairman).
Søren joined Novo A/S in 2011 as Managing Investment Director of Novo Seeds. Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine. Prior to joining Novo Seeds, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk. Søren serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reapplix and Northsea Therapeutics. Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).
Tonni has extensive medical device and life science experience and his previous positions include being CEO of Nordic Medical Group A/S, President, ELA Medical (Canada & South America), a part of Sanofi, Global Marketing Director for St. Jude Medical (Los Angeles, USA, and Japan), BU Director for St. Jude Medical EEMEA (Brussels, Belgium), Country Manager for Guidant Nordic Area and Sales Manager for Danica Biomedical. His educational background was as a medico engineer and he holds an executive MBA from the Scandinavian International Management Institute. In Vækstfonden, he is responsible for the business development of the MedTech portfolio and has several active board memberships including Fluimedix, Advalight, TeesuVac, AnyBody Technology and FBC devices.
Ulrik Spork is director of SporCon Lifescience Advisors and Salient Pharma, and chairman of the boards of Dansk Vækstkapital, Practio, MedTrace, ROS-Therapeutics, SOBEC Emea and Technolution. In addition, he is a member of the board of Statumanu. For many years and up until 2015, Ulrik Spork was part of executive management in Novo Holdings and served as Head of Venture Investments, Senior Partner in Novo Ventures, Managing Partner in Novo Growth Equity and most recently Managing Partner for Large Investments. He was previously a board member and chairman of the Danish Venture Capital and Private Equity Association (DVCA). Ulrik brings to Reapplix substantial knowledge of financing and business development in life science companies. Ulrik is a Danish citizen.
Birgit Aagaard-Svendsen is a professional board member with more than 35 years of executive international business experience. In addition Birgit has been the chairperson of the Danish committee on corporate governance. Birgit has extensive board experience with current directorships including, among others, Aker Solutions, DNV GL Group, Prosafe and West of England, for all of which she serves as the chairperson of the audit committee. She holds a Bachelor of Science in engineering from the Technical University of Denmark and a Graduate Diploma in Business Administration from the Copenhagen Business School. To Reapplix, Birgit brings strong skills in, financial and risk management, operational excellence, compliance and regulatory issues and general management. Birgit is a Danish citizen.
Cyrille Petit served as Chief Corporate Development Officer and President of Global Business Services for Smith & Nephew until 2018, and was a member of the Executive Committee from 2012. Before that, he served for 15 years with General Electric Company, where he held progressively senior Corporate Development and Strategy roles beginning with GE Capital, GE Healthcare and finally GE Transportation. He began his career in investment banking at BNP Paribas New York in 1993 and at Goldman Sachs in London between 1995 and 1997. Mr. Petit holds a Master of Arts in Finance from the HEC School of Management in Paris, France (1993).